Researchers discover circulating immune cells that drive fibrosis, revealing a new therapeutic target to prevent scar tissue ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Patients with moderate-to-severe AD can experience symptoms that disrupt sleep, thus impacting their daily activities and quality of life, said Druhan Howell, MD, a pediatric allergist and ...

New data supporting the safety and efficacy of tapinarof cream 1% (Vtama; Organon) for pediatric patients with atopic ...

The Health Service Executive (HSE) has approved BIMZELEX (bimekizumab) in Ireland for adults living with moderate-to-severe ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

New research presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting suggests ...

Jeroncellevain, a company specializing in the production of prescription pharmaceuticals, announced on November 24 that it will hold the "PDRN Total ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in ...